{"analyses":[{"groupDescription":"Treatment comparison between the pexidartinib and placebo groups at Week 25","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment comparison analysis","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Fisher's Exact Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6"},{"groupId":"OG001","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"0"}]}],"title":"Response (CR or PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Complete response (CR) and partial responses (PR) were assessed based on centrally-read magnetic resonance imaging (MRI) scans and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). A CR was defined as disappearance of all tumors and a PR was defined as at least a 30% decrease in the sum of diameters of target tumors using the baseline sum diameters as the reference.","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks Placebo: Placebo capsule matching Pexidartinib capsule for oral administration.","id":"OG001","title":"Placebo Part 1"}],"paramType":"NUMBER","populationDescription":"Best overall response was assessed in the Intent-to-Treat (ITT) population.","reportingStatus":"POSTED","timeFrame":"Week 25","title":"Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With That of Placebo Per Response Evaluation Criteria in Solid Tumors Version 1.1 at Week 25","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}